Group 1 - The core point of the article is the listing of Shenzhen Beixin Life Technology Co., Ltd. on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with the stock code 688712 [1] - The investment portfolio of the Shanghai Sci-Tech Innovation Fund has increased to a total of 185 IPOs following this listing [1]

Core Viewpoint - North Chip Life (688712) officially listed on the Sci-Tech Innovation Board on February 5, with a significant stock price increase of 183.3% on its first trading day [1] Company Overview - North Chip Life is a national high-tech enterprise focused on the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [1] - The company aims to provide transformative precision solutions for cardiovascular disease diagnosis and treatment [1] Market Performance - On the first trading day, North Chip Life opened at 50.31 yuan per share, with an intraday high increase exceeding 200%, ultimately closing at 49.64 yuan per share [1] - The total trading volume for the day reached 1.409 billion yuan, with a turnover rate of 75.88%, resulting in a total market capitalization of 20.7 billion yuan [1] Financial Projections - North Chip Life expects to achieve profitability by 2025, with projected operating revenue between 520 million yuan and 560 million yuan, representing a year-on-year growth of 64.24% to 76.88% [1] - The anticipated net profit attributable to shareholders is estimated to be between 78 million yuan and 88 million yuan, reflecting a year-on-year increase of 278.91% to 301.85% [1]

Group 1 - The company N Beixin-U (688712) was listed today, opening with a rise of 187.16%, and closing with a gain of 183.33%, with a total trading volume of 28.16 million shares and a turnover of 1.409 billion yuan, resulting in a turnover rate of 75.88% [1][2] - The company specializes in the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, aiming to provide transformative solutions for cardiovascular disease diagnosis and treatment [1] - The core products include the intravascular ultrasound (IVUS) diagnostic system, which is the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration, and the fractional flow reserve (FFR) measurement system, which is the first domestically approved product in the gold standard FFR field [1] Group 2 - The total number of shares issued by the company is 57 million, with an online issuance of 13.68 million shares at a price of 17.52 yuan per share, resulting in a final online subscription rate of 0.03264275% [2] - The initial fundraising amount is 999 million yuan, primarily directed towards the construction of an industrial base for interventional medical devices, research and development projects, working capital supplementation, and marketing network construction [2]

Core Viewpoint - North Chip Life Technology Co., Ltd. (stock code: 688712) has been listed on the Sci-Tech Innovation Board, raising nearly 1 billion yuan through the issuance of 57 million shares at a price of 17.52 yuan per share [1] Group 1: Financial Performance - The opening price of North Chip Life was 50.31 yuan, representing a 187% increase from the issuance price, with a market capitalization of 20.871 billion yuan at midday [3] - The company expects annual revenue between 520 million and 560 million yuan, reflecting a growth of 64.24% to 76.88% year-on-year [7] - Revenue for the first nine months of 2025 reached 407 million yuan, a 71.36% increase from 240 million yuan in the same period last year [7] - The projected net profit for the company in 2025 is between 78 million and 88 million yuan, indicating a year-on-year growth of 278.91% to 301.85% [7] Group 2: Company Overview - North Chip Life was established in 2015, focusing on cardiac interventional diagnostics, primarily developing, producing, and selling interventional and implantable medical devices [5] - The company’s FFR measurement system consists of the TruePhysio pressure microcatheter and the VivoCardio FFR measurement device, which aids in precise diagnosis and treatment of coronary artery disease [5] - The company reported revenues of 92.45 million yuan, 184 million yuan, and 317 million yuan for the years 2022, 2023, and 2024, respectively, with net losses of 300 million yuan, 155 million yuan, and 53.74 million yuan for the same years [5] Group 3: Shareholder Structure - Major investors include Sequoia Capital, Tiger Med, Qiming Venture Partners, and others, with Sequoia being the largest institutional shareholder [8] - Prior to the IPO, the actual controller, Song Liang, held 16.1530% of the shares directly and controlled an additional 13.414% through employee stock ownership platforms, totaling 29.5670% [8] - Post-IPO, Song Liang's direct shareholding decreased to 14.5377%, while Sequoia Capital's shareholding was reduced to 9.1583% [12][13]

Core Viewpoint - Beixin Life Technology Co., Ltd. successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking a significant milestone for the company and the medical device industry in 2024 [1][3]. Company Overview - Beixin Life is the first medical device company to successfully list under the fifth set of standards of the Sci-Tech Innovation Board and the first medical device company to list in 2024 [1]. - The company focuses on cardiovascular disease diagnosis and treatment, with core products including the IVUS system and FFR system, which are recognized for their innovation and clinical significance [3][5]. Product Highlights - The IVUS system is China's first domestically developed 60MHz high-definition and high-speed IVUS product, designed to guide percutaneous coronary intervention (PCI) strategies [3]. - The FFR system is considered the gold standard for PCI treatment guidance and has received high-level recommendations from various guidelines and expert consensus [3][5]. Research and Development - Beixin Life emphasizes independent research and technological innovation, establishing multiple core technology platforms to support product upgrades and expansions [4]. - The company has a dedicated R&D team of 109 members, with over 40% holding doctoral or master's degrees, highlighting its commitment to talent as a core competitive advantage [4]. Intellectual Property - Beixin Life has developed a comprehensive intellectual property system, holding 185 authorized patents, including 86 invention patents and 14 PCT international patent applications [5]. Market Position and Future Outlook - The company aims to leverage its listing to enhance innovation, global market expansion, and capital collaboration, positioning itself as a leader in intelligent and precise cardiovascular intervention [6]. - The cardiovascular disease intervention market is seen as a rapidly evolving sector with significant clinical demand, presenting a strategic opportunity for Beixin Life to achieve its vision of becoming a world-class medical technology enterprise [5].

Core Viewpoint - North Chip Life Technology Co., Ltd. (stock code: 688712.SH) has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with a closing price of 49.64 yuan, representing a 183.33% increase, and a total market capitalization of 20.7 billion yuan [1]. Company Overview - North Chip Life focuses on the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, with 17 approved and in-development products as of September 30, 2025 [1]. - The company aims to provide transformative solutions for cardiovascular disease diagnosis and treatment, covering five major product categories including IVUS and FFR systems [1]. Financial Performance - The company reported a cumulative loss of 686.41 million yuan as of June 30, 2025, indicating potential challenges in future cash dividends [2]. - From 2022 to 2024, the company experienced a total net loss of 473.40 million yuan, with revenues increasing from 92.45 million yuan in 2022 to 316.60 million yuan in 2024 [8][9]. Shareholding Structure - The company has no controlling shareholder, with the actual controller being Song Liang, who holds 16.15% of the shares directly and has significant influence over company decisions [2][3]. - Other shareholders are primarily financial investors who do not seek control of the company, supporting Song Liang's position as the actual controller [3]. Fundraising and Use of Proceeds - North Chip Life raised a total of 998.64 million yuan in its IPO, with a net amount of 898.89 million yuan after deducting issuance costs [5]. - The funds will be allocated to the construction of an interventional medical device industrialization base, R&D projects, and to supplement working capital, with a total planned investment of 952.21 million yuan [6][7]. Future Projections - For 2025, the company expects revenue between 520 million yuan and 560 million yuan, representing a growth of 64.24% to 76.88% year-over-year, and a net profit of 78 million yuan to 88 million yuan, indicating a growth of 278.91% to 301.85% [13].

Market Performance - The two major indices of the Sci-Tech Innovation Board opened significantly lower on February 5, with the Sci-Tech Comprehensive Index dropping by 2.37% at one point and the Sci-Tech 50 Index falling by 2.56% [1] - By the end of the trading day, the Sci-Tech Comprehensive Index closed at 1759.68 points, down 1.44%, with a total trading volume of approximately 211.8 billion yuan, showing a significant decrease compared to the previous trading day [1] - The Sci-Tech 50 Index reported 1432.52 points, also down 1.44%, with constituent stocks' total trading volume around 67.7 billion yuan, reflecting a notable reduction from the previous day [1] - A total of 173 stocks on the Sci-Tech Board rose, accounting for about 28.83%, while some semiconductor stocks saw significant gains in the afternoon, and the overall decline was led by electrical equipment stocks [1] Company Highlights - Beixin Life Technology Co., Ltd. is set to be listed on the Sci-Tech Innovation Board on February 6, 2026, focusing on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [2] - The company's core products include the intravascular ultrasound (IVUS) diagnostic system, which is the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration, and the blood flow reserve fraction (FFR) measurement system, which is the first domestic product in the FFR field approved by the same authority [2] - As of the close, Beixin Life's stock price increased by 183.33% from its issue price, with a trading volume of approximately 1.409 billion yuan and a turnover rate of 75.88% [2] Trading Statistics - Excluding Beixin Life's first trading day and the suspended stocks, the remaining 599 stocks on the Sci-Tech Board had an average decline of 1.02% on February 5, with an average turnover rate of 2.53% and a total trading volume of 210.413 billion yuan [2] - The average volatility for these stocks was 3.85% [2] - In individual stock performance, Guoxin Technology rose by 11.30%, leading the gains, while Dekeli fell by 11.36%, leading the losses [2]

Company Overview - N Beixin-U is a national high-tech enterprise focused on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, aiming to revolutionize solutions in this field [2][6] - The company's core products include the intravascular ultrasound (IVUS) diagnostic system, which is the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration (NMPA) in China, and the fractional flow reserve (FFR) measurement system, which is the first domestically approved product in the gold standard FFR field [2][6] Market Position - N Beixin-U is the first domestic medical device company to have a combination of intravascular functional FFR and imaging IVUS products, filling a gap in the domestic market and changing the reliance on imported products for precise diagnosis of coronary artery diseases in China [2][6] - The company has established a high-performance and high-barrier system for active interventional medical devices, continuously achieving successful research and commercialization of innovative products, gaining recognition in both domestic and international markets [2][6] IPO Details - The company went public today with an opening price of 50.31 yuan, reflecting a 187.16% increase from the issuance price of 17.52 yuan per share [3][7] - A total of 57 million shares were issued, with 13.68 million shares available for online subscription, and the final subscription rate was 0.03264275% [3][7] - The IPO raised approximately 999 million yuan, with funds allocated for the construction of an interventional medical device industrialization base, R&D projects, working capital, and marketing network development [3][7]

Group 1 - The company N北芯-U (688712) was listed today, opening with a significant increase of 187.16%, and closing the morning session with a rise of 185.67% [1][2] - The total trading volume for the half-day reached 21.47 million shares, with a transaction value of 1.082 billion yuan, resulting in a turnover rate of 57.85% [1][2] - The company specializes in the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, positioning itself as a national high-tech enterprise [1] Group 2 - The core products include the intravascular ultrasound (IVUS) diagnostic system, which is the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration, and the fractional flow reserve (FFR) measurement system, which is the first domestic product in the FFR field approved by the same authority [1] - Both products have entered the special review process for innovative medical devices, potentially transforming clinical practices for percutaneous coronary intervention (PCI) surgeries [1] - The company is the first domestic medical device company to offer a combination of vascular functional FFR and imaging IVUS products, filling a gap in the domestic market and changing the reliance on imported products for precise diagnosis of coronary artery diseases in China [1]

Core Insights - North Chip Life Technology Co., Ltd. has officially listed on the STAR Market, marking the first medical IPO of the year and achieving a market capitalization exceeding 20 billion yuan shortly after its debut [1][2] - The company was founded by Dr. Song Liang, who identified a critical technology gap in cardiovascular precision diagnosis and has since developed innovative medical devices [1][3] - North Chip Life is the first domestic high-end medical device company to successfully list on the STAR Market since the resumption of the fifth set of listing standards [1][5] Company Background - Dr. Song Liang, born in 1982, graduated from Wuhan University and later obtained a Ph.D. in biomedical engineering from the University of Washington [2] - After returning to China, he established a research lab at the Shenzhen Institute of Advanced Technology and began focusing on clinical needs in cardiovascular disease treatment [2][3] - The company was founded in 2015 and has developed the first domestic FFR system based on MEMS sensors, addressing a significant market gap [3] Product Development - North Chip Life has developed a total of 17 products in the cardiovascular interventional medical device field, including FFR systems and IVUS systems, with clinical applications in over 1,000 hospitals globally [3][4] - The company achieved a market-leading position with its 60MHz high-definition IVUS product shortly after its approval in China [3] Financial Performance - The company reported revenues of 92.45 million yuan in 2022, with projections of 184 million yuan and 317 million yuan for 2023 and 2024, respectively [4] - North Chip Life turned a profit before its IPO, with a net profit of 49.44 million yuan in the first half of 2025, indicating growing recognition in the global market [4] Investment and Support - The company has attracted significant investment from notable venture capital and private equity firms, including Sequoia China and Qiming Venture Partners, reflecting strong confidence in its growth potential [6][9] - North Chip Life has successfully completed multiple funding rounds, with key investors supporting its strategic vision and product development [8][9] Market Context - The IPO of North Chip Life signals a reopening of the A-share market for medical companies, with several other firms also preparing for listings [11][13] - The recent trend indicates a growing interest in domestic medical innovations, with many companies seeking to capitalize on favorable market conditions [12][14]